CEA,CA19-9在FOLFOX4方案治疗中晚期结直肠癌中的意义

目的:探讨血清肿瘤标志物癌胚抗原(CEA),糖类抗原CA19-9对结直肠癌诊断及治疗预后判断的临床意义。方法:采用微粒子捕捉免疫发光法检测血清CEA,CA19-9,共测定21例健康成人及32例病理确诊结直肠癌患者,并动态检测32例术后患者及其中9例复发患者的血清水平变化。结果:结直肠癌患者血清CEA106.02ng/ml、CA19-9 136.70U/ml,明显高于对照组5.89ng/ml和17.77U/ml,两组比较有显著统计学差异;32例患者术后血清CEA 15.13ng/ml,CA19-9 29.86U/ml,较术前血清CEA、CA19-9浓度均有显著降低,差异有统计学意义;结直肠癌患者血清CEA,CA19-9水平随临床病理分化程度差而增高,组间比较差异有统计学意义;9例复发患者术前、综合治疗术后及复发后血清CEA分别为176.82、18.83及192.27ng/ml,血清CA19-9分别217.88、37.29及116.50 U/ml,各组间比较均有显著统计学差异。结论:CEA、CA19-9可成为结直肠癌辅助诊断、治疗评估预后及预测复发转移有意义的肿瘤标志物。

The value of derum CEA and CA19-9 in evaluating the clinical effects of advanced colorectal cancer treated with FOLFOX4

Objective：To study the significance of serum CEA、CA19-9 in evaluating the effects of advanced colorectal cancer treated with FOLFOX4.Metholds： The serum CEA、CA19-9 of 21 health adults were measured.The serum CEA、CA19-9 of 32 patients with advanced colorectal cancer treated with FOLFOX4 were measured before and after treatment.Results： The levels of CEA5.89ng/ml、CA19-9 17.77U/ml with 21 health adults were significantly lower than those in colorectal cancer patients CEA106.02ng/ml、CA19-9 136.70U/ml.The levels of CEA 15.13ng/ml、CA19-9 29.86U/ml with postoperative patients were significantly lower than those in preoperative patients.The levels of CEA、CA19-9 of colorectal cancer patients were increased with the cell differentiation degree.The more the cell differentiation,The higher the levels of CEA、CA19-9.There were significant difference with different cell differentiation groups.In addition,the CEA of 9 recurrence patients in preoperation,postoperation and post recurrence were 176.82、18.83 and 192.27ng/ml,the CA19-9 were 217.88、37.29 and 116.50 U/ml.There were significant difference with different period.Conclusion： The levels of CEA and CA19-9 can be used as useful tumor markers with colorectal cancer patients which can used in auxiliary diagnosis、treatment evaluation and prognosing recurrence.